Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
In recent years, there has been increased focus on cognitive side effects of sleep-inducing
medications that may contribute to unusual behavior during unexpected awakenings during the
night. Concerns regarding these side effects have led to a class Food and Drug Administration
(FDA) warning for all sleep-inducing medications. Almorexant is an experimental
sleep-inducing medication in a new class of medications that is being extensively developed
by multiple pharmaceutical companies. Medications in this class block wake/arousal centers in
the brain that function with proteins called hypocretins. The goal of this study is to
evaluate the impact on cognitive performance of almorexant vs. zolpidem (an approved sleep
aid) or placebo.
Phase:
N/A
Details
Lead Sponsor:
Northern California Institute of Research and Education
Collaborators:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command